preclinical populations with to which our likely would respond very are AI PEDAL cancer we Cancer platform, types a with treatment you CRH glutaminase utilize drug thank inhibitor good research compound patient everyone. announce were platform, we year, determine compounds. Horizons, Glenn, and to this our whereby to Research morning, drug pleased most March to In and these much, very to evaluate of discovery collaboration several
more has innovative the cancer a largest the in the the Cancer independent engine CRH a drugs is core an world. research XXX XX than currently cancer annual $XXX more another As at stages in of X,XXX of of spend million, funder CRH on candidates researchers, the various than of network and reminder, of Research UK, market development. research
from am I results might pursuing with initial provided prioritizing strongest these significant most we By is themselves, ideal this projects milestone a the because research the as of in tumor results for results significant PEDAL, and succeed we CRH to resources that which, time CRH to have collaboration, by but Today, terms matter output imagine, the not in company, the achieve clinic. save for candidates announce the in of pleased a of types you were to able the that weeks. of very only can upon likely are the development those based only our
level lab, XXX,XXX than believe bench because than our and else predict more of of development. we biobank we introduce CLIA-certified earliest and actual proprietary tumor can into support the our of able wet drug very heterogeneity of stages accuracy with a with can With clinical we silico experimentation. anyone in are samples tumor success and higher probability And predictions patients the to we modeling degree
further our these for of potential large development seek now licensing With CRH in significant and companies pharmaceutical reasons. deals prioritize hand, X data compounds can for with This the development. is
from event said, as we completed the additional way first as because second, I for CRH. sales royalties; as has now for campaign, are eligible potential First, development pave the commercialization success executed that deal a we several well weeks, was should licensing in which, and of the because milestones in believe projects this and
business that significance had with our relationship development a this very impact the external has the It our is positive campaign validation difficult on And initial CRH efforts of overstate elsewhere. to provides.
date discovered to of believe subsequently drugs progress which are pleased a and and is foundational how developed. forefront The to AI growth. have am emergence changing foundation with created and at transformation. drive fundamentally we this exciting our on And future solid I are of the we
generally But that It lower risk drug well insight of make never of commercial decisions candidates into likelihood and of greater approximately clinical and unique response XX% gain known our financial our commercial received success. with the can drug and drug heterogeneous accepted is strategic partners development future capabilities, approval. with confidently
to announced that was retrospective learning short- UPMC We of that now with completed development purpose survival we long-term in machine our successfully multi-omic models Turning Pittsburgh. study quarterly could significant cancer. to week study have last a The this another since Magee-Womens just overall and multiyear build update. last in ovarian Hospital predict
sets multi-omic identify The The from of of patients largest overall drive from to one derived study or time of survival key that cancer ovarian first at the XXX tumor the intervention. data study designed endpoints. samples the diagnosis obtained was features surgical incorporated
These to accuracy. both of will presented strong And with multiple models XXXX. able considering to are medical deliver in fact, initiatives high in future and these further have utilize at And predictive been data meetings national we expand be we levels cohorts.
High-grade lowest our The of make learning ovary up cases cancer made multi-omic carcinomas, obvious is because here models our have survival most define for identify prognostic the the example, within have ovarian to rate. machine subgroups ovarian technology power certain serous and the and cancer. potential of
prognostic concerned, there features next the model. features about are as includes slides originate were digital that our having is from as This that far certainly As pathology to an importance opportunity more library. for own identified steps learn
the affecting support tools. and patients goal Ultimately, these cancer survival here to of overall patients tailoring models treatment of an ovarian of development invaluable of cancer support clinical rescue positively models the support and could intellectual Clearly, the opportunity there's an and to ovarian beneficial discovery individual specific for these the in the identify drug decision is to the or of that therapies explore property to repurposing process platform. of and AI-driven significant development, with predictive
are to would other projects take I to moment that a now like significant ongoing. review some
February and artificial utilizing this and may develop precision intelligence. Predictive first-ever of a year, genomics-based to Cvergenx discovery in radiation to the drug Oncology approach partnership As recall, you announced therapy
was objective to Since this biomarker maximize exposures Oncology's changes predict databases. radioprotector intelligence radiosensitivity more the radiosensitizer in expertise have we for identify expression different proficiency for developed drugs. X,XXX using of Predictive in combined and The power radiation artificial trained drug novel collaboration and to well-established development models therapy and of Cvergenx then, leverage to evaluated, or in gene than
be protect our from space we radiation radioprotective flight. preliminary to to NIH tumor the submitted drugs a during proposal step and the astronauts effects therapy. to also the Based energy proposal SBIR for have in on from radiation in results to An for safeguard nuclear patients receiving search and industry NASA setting military sensitivity of from propose X workers clinical to the radiation models, those tissue increase drugs to the to submitted will the of radiation
time utilize evaluate guide screening of in most of silico PEDAL know, biobank integral Most physical As laboratory both X valuable are Oncology's discovery and drug drug to to minimize than and we projects design experiments. to data, on assets the order in samples experiments material PEDAL spent which and the more models. to Predictive XXX,XXX are tumor all of platform, our drug our direct the response and repository current
radiosensitizing radiation driving resistance in first, respect several to Oncology or for therapeutic to Predictive data important between leveraged those is or commercialization: therapeutic the of be and patient between of collaboration screen drugs. repurpose develop effect and ways identify, individuals screen to or sensitivity improve radiotherapy; resistant sets, interactions sensitive and Cvergenx third, may radioprotective tumor for with novel to second, or samples or The to compounds; combine expansion which
with simultaneously, toxicology drug addition developed proceed studies. that Separately And in company we has are collaborating candidate to next-generation an a we FluGen novel biotech vaccine disease but Phase their and already been have enabled the related formulation IIb to for international NIH. which a contracts existing successfully respiratory submitted on for biopharma with pharmaceutical with grant a company for a to to that protein companies,
where and over these of the product. Several just XX interest companies with X endotoxin purchase expressed in pharmaceutical have recently, our our we different Most from we BIO-Europe, services formulation days. met of companies returned
In addition, conditions the optimum new enables for stability in screening to to high-volume HSC, proprietary expressed Chromatography rapid platform, purchasing Throughput referred interest X solubility and our determine Self-Interaction other companies as High vaccines. to more forward These of to technology early impact in of spectrum look our projects. announcements the broad contracts a we near drug versatility to discovery such future. that positively And point the and development
do make class of hyper It For take contracts, progress GPCR, is to is a proteins do high-value are example, and we cancer market continue engagements while we an that we G discovery. discovery worth important these in express an to focused recognize PEDAL repeating emerging receptors, securing represent time. method that clearly protein-coupled that on stabilize drug membrane drug on which novel
quality To our formulation fee-for-service have business, because every is play active control provided a testing basis. support protein a of almost pharmaceutical relevant to are field on biologics in very also and medicine. therapeutics efforts, these wherein development role This we meaningful a partners development
therapeutics body. From to and dose must antibodies in has the increased optimal therapies of therapy circulated, be to properly hormone the be protein for and an brought to number But frequency and delivered these absorbed market enzymes of dramatically. treatment, effective, the
out drug formulations drug production the more unlike company this because alternative the I to efficiently PEDAL Not is discovery enable supplement positioned formulation a of PEDAL predictive point discovery, identify us to accuracy biologics process, our viable of building platform formulations for accelerate generate this streamline pipeline efficient the applications. revenue commercial and contracts. capabilities milestone-driven to well and and near-term for
last care executive individuals Advisory relevant finance him expertise: highly has quarter, Harris, as of broad companies. a Jr., health served senior X of creation appointment yet clinical experience; and Dr. business of finally, with range and operational biopharmaceutical wealth we with Business brings a who and And Andrew A. the who veteran, Bernard a finance announced of for Einhorn, the Board diverse
our the Board's in efforts perspectives our momentum unique deliver will drug be lasting Business value accelerate, continues our to insight, creating our to and partners invaluable expertise for solutions to and As shareholders. development Advisory
out would and the Board. to diversity many of seeking We as who Business outstanding add Advisory are perspectives to seek we backgrounds candidates round our
Accounting sciences point, introduce public as and this Interim I like CFO Officer, in and for served life August new has served several Principal At Josh our our Chief joined Josh Officer. to private Josh us Financial Financial companies. and Principal Blacher. Officer as would
he introducing had helping on and has board. finance have and efficiencies Josh of more focus Investor already I'm helping Relations growth And more and a in to a businesses top some line impact positive our accounting on program. out department on operating the robust roll pleased profitability,
turn the call I financials. Josh At review over to point, this the Josh? will to
